The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sintilimab in combination with cetuximab and chemotherapy as first-line treatment for RAS/BRAF wild-type advanced colorectal cancer (CALLIOPSIS): An open-label, non-comparative, phase 1b/2 dose escalation and expansion trial.
 
Ying Wang
No Relationships to Disclose
 
Shanshan Zheng
No Relationships to Disclose
 
Yibo Gao
No Relationships to Disclose
 
Yanrong Zhu
No Relationships to Disclose
 
Peng Sun
No Relationships to Disclose
 
Shou Luo
No Relationships to Disclose
 
Zhenzhen Luo
No Relationships to Disclose
 
Zesong Chen
No Relationships to Disclose
 
Jugao Chen
No Relationships to Disclose
 
Xuhao Cai
No Relationships to Disclose
 
Yanjiong He
No Relationships to Disclose
 
Mingrui Ma
No Relationships to Disclose
 
Yonggang Yu
No Relationships to Disclose
 
Shi Jin
No Relationships to Disclose
 
Dongmei Lan
No Relationships to Disclose
 
Yinggang Chen
No Relationships to Disclose